Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Feb
04
Today In Oncology
American College of Surgeons Publishes Annual NCDB Report
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer
AI Tool Predicts Cardiac Events in Patients With Cancer and Acute Coronary Syndrome
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo